GlassScriptPhysician profile
Anne V Hale
NPI 1063409274
$3,647.88
in general payments reported to CMS, 2019-2025
24 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $630 · 2021: $618 · 2022: $618 · 2023: $509 · 2024: $176 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $664.59 | 2019-2023 | Balcoltra |
| Abbvie INC. | $658.72 | 2020-2025 | |
| Merz North America, INC. | $603.71 | 2019-2022 | |
| Lupin INC. | $255.08 | 2019-2020 | |
| Exeltis, USA INC. | $234.75 | 2019-2025 | Slynd |
| Organon LLC | $199.58 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $199.13 | 2020-2021 | |
| Therapeuticsmd, INC. | $145.11 | 2019-2022 | |
| Boston Scientific Corporation | $108.70 | 2020 | |
| Shield Therapeutics INC | $76.03 | 2023-2024 | Accrufer |
| Vertical Pharmaceuticals, LLC | $71.67 | 2019 | |
| Sage Therapeutics, LLC | $70.61 | 2024-2025 | Zurzuvae |
| Duchesnay USA Incorporated | $59.84 | 2019 | |
| Mayne Pharma Commercial LLC | $51.11 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $50.90 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $38.14 | 2022-2023 | Twirla |
| Minerva Surgical, INC | $31.01 | 2019-2020 | |
| Galderma Laboratories, L.P. | $30.42 | 2020-2022 | |
| Astellas Pharma US INC | $20.41 | 2019 | |
| Aspira Women'S Health INC | $19.14 | 2024 | Ova1 |
| Pfizer INC. | $17.42 | 2024 | |
| Supernus Pharmaceuticals, INC. | $15.76 | 2025 | Qelbree |
| Exact Sciences Corporation | $13.57 | 2024 | Cologuard Collection Kit |
| Scynexis, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.